Bertolaccini Luca, Pardolesi Alessandro, Forti Parri Sergio Nicola, Bonfanti Barbara, Brandolini Jury, Solli Piergiorgio
Department of Thoracic Surgery, AUSL Bologna, Maggiore Teaching Hospital, Bologna, Italy.
Department of Thoracic Surgery, AUSL Romagna Teaching Hospital, Forlì, Italy.
J Thorac Dis. 2018 Jan;10(1):498-502. doi: 10.21037/jtd.2017.11.135.
In recent years, retrospective analyses have suggested that an oligometastatic state could exist, but the best evidence to date that a temporary oligometastatic disease exists for lung cancer mainly derives from the survival data on retrospective patients underwent surgical resection of a single M1 site and all intrathoracic disease. The critical determinates of long-term survival include definitive treatment of the primary non-small cell lung cancer (NSCLC), a single organ site of synchronous or metachronous disease, a long disease-free interval between treatment of the primary NSCLC and development of metastases, and the absence of intrathoracic lymph node (N0) disease. The ongoing development of innovative approaches to local therapy and treatment directed to the oligometastatic sites should be defined in future studies.
近年来,回顾性分析表明可能存在寡转移状态,但目前关于肺癌存在暂时性寡转移疾病的最佳证据主要来自对接受单个M1部位及所有胸内疾病手术切除的回顾性患者的生存数据。长期生存的关键决定因素包括对原发性非小细胞肺癌(NSCLC)的确定性治疗、单一器官部位的同步或异时性疾病、原发性NSCLC治疗与转移发生之间的长无病间期,以及无胸内淋巴结(N0)疾病。未来研究应明确针对寡转移部位的局部治疗和治疗的创新方法的持续发展。